Profile data is unavailable for this security.
About the company
TriSalus Life Sciences, Inc. is an oncology focused medical technology business providing drug delivery technology with the goal of improving therapeutics delivery to liver and pancreatic tumors. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. Its two Food and Drug Administration (FDA) cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. Additionally, the Company is exploring the integration of its technology with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of liver and pancreatic indications.
- Revenue in USD (TTM)24.74m
- Net income in USD-57.21m
- Incorporated2020
- Employees112.00
- LocationTriSalus Life Sciences Inc6272 W. 91st Ave.WESTMINSTER 80031United StatesUSA
- Phone+1 (415) 336-8917
- Fax+1 (302) 636-5454
- Websitehttps://trisaluslifesci.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Invivyd Inc | 2.26m | -203.84m | 119.44m | 94.00 | -- | 0.8493 | -- | 52.76 | -1.80 | -1.80 | 0.0199 | 1.18 | 0.0092 | -- | 1.13 | 24,085.11 | -82.73 | -- | -96.25 | -- | 96.11 | -- | -9,003.40 | -- | 4.57 | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
| Century Therapeutics Inc | 2.69m | -129.89m | 119.89m | 152.00 | -- | 0.6092 | -- | 44.65 | -1.86 | -1.86 | 0.0372 | 2.31 | 0.0068 | -- | -- | 17,664.47 | -33.04 | -- | -34.83 | -- | -- | -- | -4,837.73 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
| Coya Therapeutics Inc | 9.55m | -10.10m | 121.13m | 8.00 | -- | 3.13 | -- | 12.68 | -0.7726 | -0.7726 | 0.7589 | 2.32 | 0.3512 | -- | -- | 1,194,290.00 | -37.13 | -- | -40.92 | -- | -- | -- | -105.71 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| Alto Neuroscience Inc | -100.00bn | -100.00bn | 121.32m | 78.00 | -- | 0.6746 | -- | -- | -- | -- | -- | 6.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.053 | -- | -- | -- | -31.02 | -- | -- | -- |
| Allakos Inc | 0.00 | -178.75m | 122.40m | 131.00 | -- | 1.68 | -- | -- | -2.03 | -2.03 | 0.00 | 0.8142 | 0.00 | -- | -- | 0.00 | -87.64 | -42.71 | -97.01 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
| Leap Therapeutics Inc | 0.00 | -60.34m | 124.36m | 54.00 | -- | 1.89 | -- | -- | -2.00 | -2.00 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -67.81 | -80.06 | -80.19 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| INmune Bio Inc | 42.00k | -41.27m | 125.50m | 11.00 | -- | 3.24 | -- | 2,988.00 | -2.18 | -2.18 | 0.0022 | 1.74 | 0.0007 | -- | 0.0228 | 3,818.18 | -71.48 | -37.82 | -94.55 | -41.86 | -- | -- | -98,266.66 | -14,901.03 | -- | -34.08 | 0.0606 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| TriSalus Life Sciences Inc | 24.74m | -57.21m | 130.73m | 112.00 | -- | -- | -- | 5.29 | -1.70 | -1.70 | 0.8372 | -0.8892 | 1.00 | 1.23 | 7.28 | 220,848.20 | -220.73 | -- | -2,149.76 | -- | 87.65 | -- | -219.71 | -- | 2.04 | -100.87 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| Avalo Therapeutics Inc | 820.00k | -8.14m | 133.15m | 19.00 | -- | 5.88 | -- | 162.37 | -10.96 | -10.96 | 0.1976 | 2.35 | 0.0128 | -- | 0.6467 | 43,157.89 | -12.46 | -99.64 | -26.07 | -154.42 | 182.20 | 84.69 | -970.49 | -613.58 | -- | -6.69 | 0.00 | -- | -89.34 | -22.83 | 24.28 | -- | -22.48 | -- |
| Inovio Pharmaceuticals Inc | 591.86k | -121.64m | 133.72m | 122.00 | -- | 1.38 | -- | 225.93 | -5.11 | -5.11 | 0.0248 | 3.73 | 0.0032 | -- | 0.6652 | 4,851.31 | -66.32 | -59.52 | -84.33 | -71.29 | -- | -- | -20,552.24 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
| Generation Bio Co | 18.58m | -145.47m | 136.93m | 174.00 | -- | 1.31 | -- | 7.37 | -2.19 | -2.19 | 0.2797 | 1.56 | 0.059 | -- | 56.31 | 106,793.10 | -46.16 | -36.96 | -51.29 | -39.21 | -- | -- | -782.87 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -30.58m | 137.77m | 140.00 | -- | 45.87 | -- | -- | -1.18 | -1.18 | 0.00 | 0.056 | 0.00 | -- | -- | 0.00 | -95.14 | -- | -154.95 | -- | -- | -- | -- | -- | -- | -21.58 | 0.8416 | -- | -- | -- | -11.06 | -- | -- | -- |
| P3 Health Partners Inc | 1.40bn | -69.48m | 139.65m | 400.00 | -- | 0.3785 | -- | 0.0996 | -0.5821 | -0.5821 | 11.56 | 1.03 | 1.56 | -- | 10.97 | 3,507,143.00 | -20.51 | -- | -110.70 | -- | 0.6223 | 0.1781 | -13.17 | -56.93 | -- | -9.67 | 0.2686 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
| Candel Therapeutics Inc | 0.00 | -49.99m | 143.42m | 42.00 | -- | -- | -- | -- | -1.70 | -1.70 | 0.00 | -0.321 | 0.00 | -- | -- | 0.00 | -117.35 | -- | -158.61 | -- | -- | -- | -- | -- | -- | -32.70 | 2.36 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
Data as of Nov 13 2024. Currency figures normalised to TriSalus Life Sciences Inc's reporting currency: US Dollar USD
7.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wealthcare Advisory Partners LLCas of 30 Sep 2024 | 643.74k | 2.20% |
| Duquesne Family Office LLCas of 30 Jun 2024 | 426.92k | 1.46% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 411.00k | 1.40% |
| Exos Asset Management LLCas of 30 Jun 2024 | 167.61k | 0.57% |
| Geode Capital Management LLCas of 30 Jun 2024 | 137.89k | 0.47% |
| Millennium Management LLCas of 30 Jun 2024 | 122.90k | 0.42% |
| Lido Advisors LLCas of 30 Jun 2024 | 44.41k | 0.15% |
| HRT Financial LP (US)as of 30 Jun 2024 | 35.54k | 0.12% |
| Connecticut Wealth Management LLCas of 30 Jun 2024 | 32.88k | 0.11% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 30.27k | 0.10% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
